Figure 2
From: Cell-free DNA 5-hydroxymethylcytosine is an emerging marker of acute myeloid leukemia
A 5hmC signature differentiates AML patients from controls. (a) Principal component analysis (PCA) in AML patient samples at registration time points and controls using normalized read counts from the 5hmC signature of 70 genes. (b) Unsupervised hierarchical clustering of the 5hmC signature of 70 genes in AML patient samples at registration time points and controls. (c) Boxplot of weighted-diagnostic scores (wd-scores) in controls and AML samples in both training (n = 62) and validation sets (n = 42). Black dashed line represents a cutoff score of 0.263 developed from the training set. P < 0.001, comparison of any of the AML groups to the control group in both training and validation sets. Center line represents median, bounds of box represent 25th and 75th percentiles, and whiskers are Tukey whiskers. (d) Boxplot of wd-scores in controls and other AML samples that were not included in the training, validation, and test sets. Non-HSCT, did not receive hematopoietic stem cell transplantation (n = 26); HSCT Non-CR, received hematopoietic stem cell transplantation and not in complete remission (n = 13); HSCT CR, received hematopoietic stem cell transplantation and in complete remission (n = 21). Center line represents median, bounds of box represent 25th and 75th percentiles, and whiskers are Tukey whiskers. (e) Receiver Operating Characteristics (ROC) analysis of wd-score calculated from the 5hmC signature of 70 genes in validation and test sets. AUC area under curve. CI 95% confidence interval. (f) Boxplot of wd-scores in additional AML samples and controls in the test set. Controls, n = 39. Non-CR did not achieve complete remission, n = 14. CR complete remission, n = 22. Center line represents median, bounds of box represent 25th and 75th percentiles, and whiskers are Tukey whiskers.
